$--
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-78.68 Mln
EBITDA
$-115.54 Mln
Net Profit
$-109.56 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Phio Pharmaceuticals Corp (PHIOW)
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Phio Pharmaceuticals Corp (PHIOW)
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762... which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Read more
-
Pres, CEO & Director
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D.
-
Pres, CEO & Director
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D.
-
Headquarters
Marlborough, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Phio Pharmaceuticals Corp (PHIOW)
What is the current share price of Phio Pharmaceuticals Corp (PHIOW) Today?
The share price of Phio Pharmaceuticals Corp (PHIOW) is $0.00 (NASDAQ) as of 06-Jan-2022 EDT. Phio Pharmaceuticals Corp (PHIOW) has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Phio Pharmaceuticals Corp (PHIOW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2020 |
-0.14 |
0.09 |
2019 |
0.00 |
0.01 |
2018 |
0.00 |
0.00 |
2017 |
0.00 |
0.00 |
2016 |
0.00 |
0.00 |
What is the 52 Week High and Low of Phio Pharmaceuticals Corp (PHIOW)?
The 52-week high and low of Phio Pharmaceuticals Corp (PHIOW) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Phio Pharmaceuticals Corp (PHIOW)?
Phio Pharmaceuticals Corp (PHIOW) has a market capitalisation of $ 0 Mln as on 06-Jan-2022. As per SEBI classification, it is a company.
Should I invest in Phio Pharmaceuticals Corp (PHIOW)?
Before investing in Phio Pharmaceuticals Corp (PHIOW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.